A novel endogenous inhibitor for the treatment of diabetic nephropathy [ 2017 - ]

Research Grant

Researchers: Prof Mark Cooper (Principal investigator) ,  Dr Phillip Kantharidis

Brief description In various kidney diseases including the most common cause of end stage kidney disease, diabetic nephropathy, identifying the molecular mechanisms responsible for kidney failure are needed to assist in defining new targets and to develop more effective treatments. The proposed studies highlight the potential of a naturally occurring endogenous molecule called Lipoxin, as a modulator of kidney injury which may provide us with a novel approach to tackle the problem of diabetic nephropathy.

Funding Amount $774,606.00

Funding Scheme Project Grants

Notes Standard Project Grant